期刊文献+

短尾蝮蛇毒纤溶酶原激活剂动脉溶栓的实验研究 被引量:2

Experimental study of thrombolysis in artery by plasminogen activator of Gloydius brevicaudus venom(GBV-PA)
暂未订购
导出
摘要 目的观察短尾蝮蛇毒纤溶酶原激活剂不同剂量溶栓的量效关系;对短尾蝮蛇毒纤溶酶原激活剂、瑞替普酶、尿激酶溶栓结果进行比较,评价短尾蝮蛇毒纤溶酶原激活剂溶栓效果。方法在36只成年毕格犬建立急性脑栓塞模型,随机分为生理盐水组、瑞替普酶组、尿激酶组、短尾蝮蛇毒纤溶酶原激活剂大剂量组(75μg/kg)、中剂量组(37.5μg/kg)及小剂量组(18.75μg/kg)6组,分别予以相应干预处理。溶栓后分别于60、120、180、240分钟行颈内动脉造影观察栓塞动脉再通情况并抽取静脉血液测定TT、PT、APTT、FIB及DD。结果(1)溶栓后2小时GBV-PA大剂量组(75μg/kg)、中剂量组(37.5μg/kg)、小剂量组(18.75μg/kg)及生理盐水组血管再通率分别为86.7%、52.4%、33.3%和0.00%,大剂量组血管再通率明显高于中、小剂量组。(2)溶栓后2小时瑞替普酶组、GBV-PA大剂量组、尿激酶组的血管再通率分别为88.9%、86.7%和57.9%,瑞替普酶组、GBV-PA大剂量组均高于尿激酶组,GBV-PA大剂量组和瑞替普酶组两者之间无统计学差异。结论短尾蝮蛇毒纤溶酶原激活剂动脉溶栓效果呈剂量依赖性;大剂量短尾蝮蛇毒纤溶酶原激活剂比尿激酶具有更强的血栓溶解作用,与瑞替普酶溶栓效果相当。 Objective To observe the relationship between thrombolytic effect and doses of plasminogen activator of Gloydius brevicaudus venom (GBV-PA); To evaluate the intraarterial thrombolytic effect of plasminogen activator of Gloydius brevicaudus venom(GBV-PA) compared with reteplase(r-PA) and urokinase(UK). Methods The model of acute left cerebral embolism was established with interventional technique in 36 adult beagle dogs,which were randomly divided into 6 groups,including control group,reteplase group,urokinase group,GBV-PA high-dose group(75μg/kg),middle-dose group (37.5μg/kg) and low-dose group(18.75μg/kg). Each group was dealt with by correspongding thrombolytics respectively.Angiography of left internal carotid artery were performed after thrombolysis 60,120,180,240 minutes to observe the recanalization of embolized arteries.Blood samples were collected to determine thrombin time (TT),prothrombin time (PT),activated partial thromboplastin time(APTT),fibrinogen(FIB)and D-Dimer(DD). Results (1)The recanalization rate after thrombolysis 2 hours was 86.7% in GBV-PA high-dose group,52.4% in GBV-PA middle-dose group,33.3% in GBV-PA low-dose group and 0.00% in control group. There was significant statistical difference between every two-groups. (2)The recanalization rate after thrombolysis 2 hours was 88.9% in reteplase group,86.7% in GBV-PA high-dose group and 57.9% in urokinase group. The vascular recanalization rate in GBV-PA high-dose group and reteplase group was higher than that in urokinase group. There was no significant statistical difference in vascular recanalization rate between GBV-PA high-dose group and reteplase group. Conclusion The thrombolytic effect of GBV-PA was dose-dependent;The thrombolytic power of high-dose GBV-PA was stronger than that of urokinase.But there was no significant difference in vascular recanalization rate between high-dose GBV-PA and reteplase.
出处 《当代医学》 2010年第11期212-215,共4页 Contemporary Medicine
关键词 短尾蝮蛇毒纤溶酶原激活剂 瑞替普酶 尿激酶 溶栓 动脉 plasminogen activator of Gloydius Brevicaudus venom urokinase reteplase thrombolysis artery
  • 相关文献

参考文献5

二级参考文献37

  • 1王晴川,许云绿,刘广芬.一种简易的家兔颈动脉血栓模型形成方法和蕲蛇酶的溶栓作用[J].中国药理学通报,1993,9(3):228-229. 被引量:15
  • 2黎渊弘,黎肇炎,林发全,黄炳轮.短尾蝮蛇毒中磷脂结合抗凝蛋白的分离纯化及鉴定[J].中国药理学通报,2006,22(7):831-835. 被引量:13
  • 3崔立斌 马清俊.vt-PA缺失突变体K2P t-PA的基因工程研究[A]..全军生物化学与分子生物学研究进展[C].,1998.p104.
  • 4刘永军.基因工程产品reteplase[OL].http://www.hx863.com.,2002-07-23.
  • 5上海新生源医药研究有限公司.组织型纤溶酶原激活物突变体的生产方法[P].中国发明专利,申请号:01145280.3.2002.
  • 6叶林柏 郜金荣.重建人t-PA及表达重建人t-PA蛋白的工程菌株[P].CP0015972.0.2001-01-24.
  • 7黄建英 牛瑞芳.细胞工程法制备t-PA及其应用[J].科学技术成果公报,1993,5:75-75.
  • 8国家药品监督管理局注册司.关于已批准临床研究的新药品种公告(第43号).药监注函[2002]113号[Z].,2002-4-22..
  • 9江苏吴中实业股份有限公司.2002年第3季度报告[N].上海证券报,2002-10-23.
  • 10Markland F S. Snake venoms and the hemostatic system[ J]. Toxicon, 1998,36(12) :1749 -800.

共引文献62

同被引文献7

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部